Cases & Deals

  • Home
  • Practices
  • Hope Pharmaceuticals files two IPR petitions challenging all claims of two Fennec patents relating to sodium thiosulfate

Share

Hope Pharmaceuticals files two IPR petitions challenging all claims of two Fennec patents relating to sodium thiosulfate

October 2021

Client(s) Hope Pharmaceuticals

Jones Day represents Hope Medical Enterprises, Inc. ("Hope Pharmaceuticals") in two petitions for inter partes review ("IPR") at the United States Patent Office's Patent Trial and Appeal Board ("PTAB"). The petitions challenge the validity of all claims of two patents for which Fennec Pharmaceuticals, Inc. is the patent owner or exclusive licensee. The claims are directed to certain forms of sodium thiosulfate and cover composition, synthesis, measurement, and a method of treatment.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.